Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

(2017) Liang Xu et al.   EBioMedicine

Sodium Intake Regulates Glucose Homeostasis through the PPARδ/Adiponectin-Mediated SGLT2 Pathway

(2016) Yu Zhao et al.   Cell Metabolism

Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes

(2016) Ele Ferrannini et al.   DIABETES

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

(2016) Simon A. Hawley et al.   DIABETES

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

(2016) François Briand et al.   DIABETES

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice

(2016) Atsushi Obata et al.   ENDOCRINOLOGY

Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells

(2016) J. Jager et al.   JOURNAL OF INTERNAL MEDICINE

Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

(2015) John R. White   ANNALS OF PHARMACOTHERAPY

Adiponectin Enhances Cold-Induced Browning of Subcutaneous Adipose Tissue via Promoting M2 Macrophage Proliferation

(2015) Xiaoyan Hui et al.   Cell Metabolism

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

(2015) Shirong Qiang et al.   Diabetology & Metabolic Syndrome

Differential Effects of Leptin and Adiponectin in Endothelial Angiogenesis

(2015) Raghu Adya et al.   Journal of Diabetes Research

Ontogeny and Polarization of Macrophages in Inflammation: Blood Monocytes Versus Tissue Macrophages

(2015) Adwitia Dey et al.   Frontiers in Immunology

Eosinophils and Type 2 Cytokine Signaling in Macrophages Orchestrate Development of Functional Beige Fat

(2014) Yifu Qiu et al.   CELL

Ablation of PRDM16 and Beige Adipose Causes Metabolic Dysfunction and a Subcutaneous to Visceral Fat Switch

(2014) Paul Cohen et al.   CELL

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

(2014) David Polidori et al.   DIABETOLOGIA

Crosstalk between Adipocytes and Immune Cells in Adipose Tissue Inflammation and Metabolic Dysregulation in Obesity

(2014) Jin Young Huh et al.   MOLECULES AND CELLS

Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice

(2014) Naoto Terami et al.   PLoS One

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

(2014) Michael Nauck   Drug Design Development and Therapy

Macrophage Polarization in Obesity and Type 2 Diabetes: Weighing Down Our Understanding of Macrophage Function?

(2014) Michael James Kraakman et al.   Frontiers in Immunology

Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes

(2013) Kinyui Alice Lo et al.   BIOSCIENCE REPORTS

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Adaptive thermogenesis in adipocytes: Is beige the new brown?

(2013) J. Wu et al.   GENES & DEVELOPMENT

Macrophage plasticity and polarization in liver homeostasis and pathology

(2013) Antonio Sica et al.   HEPATOLOGY

The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors

(2013) S. Cangoz et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages

(2013) Ari B. Molofsky et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Beyond Stem Cells: Self-Renewal of Differentiated Macrophages

(2013) M. H. Sieweke et al.   SCIENCE

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study

(2012) S. M. A. J. Tielemans et al.   DIABETOLOGIA

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

(2012) Akiko Sarashina et al.   Drug Metabolism and Pharmacokinetics

FGF21 regulates PGC-1  and browning of white adipose tissues in adaptive thermogenesis

(2012) f. M. Fisher et al.   GENES & DEVELOPMENT

Macrophage plasticity and polarization: in vivo veritas

(2012) Antonio Sica et al.   JOURNAL OF CLINICAL INVESTIGATION

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats

(2012) James J. Devenny et al.   Obesity

Inflammatory Mechanisms in Obesity

(2011) Margaret F. Gregor et al.   Annual Review of Immunology

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis

(2011) Khoa D. Nguyen et al.   NATURE

Macrophages, Inflammation, and Insulin Resistance

(2010) Jerrold M. Olefsky et al.   Annual Review of Physiology

Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target

(2009) R. Santer et al.   Clinical Journal of the American Society of Nephrology

Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters

(2009) Markus Feuerer et al.   NATURE MEDICINE

PRDM16 controls a brown fat/skeletal muscle switch

(2008) Patrick Seale et al.   NATURE